Digestive Diseases and Sciences

, Volume 61, Issue 9, pp 2488–2491 | Cite as

Self-Limited Sepsis Syndrome Following Fecal Microbiota Therapy for Refractory C. difficile Infection

  • Sundeep Singh
  • Emily Jing
  • Neil StollmanEmail author
Stanford Multidisciplinary Seminars

Clinical Presentation and Evolution

A 56-year-old woman who had denied any prior travel or sick contacts was initially evaluated in the Emergency Department with complaints of 7 days of watery, non-bloody diarrhea, associated with 1 day of nausea and vomiting. She reported having 8–10 bowel movements per day, a frequency that was progressively increasing. One month prior to admission, she had been treated with 10 days of amoxicillin–clavulanate for bacterial sinusitis. Three days prior to admission, she took two doses of loperamide at home without any decrease in the frequency of bowel movements. Ciprofloxacin had been prescribed the day prior to admission without any clinical improvement. She had no significant past medical or surgical history, except for mild depression that was treated with sertraline.

Upon initial evaluation in the Emergency Department, she had normal vital signs and a normal physical examination. Laboratory values were notable for a WBC 31,000/µL with 42 % band...


Vancomycin Metronidazole Bowel Movement Loperamide Clavulanate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest



  1. 1.
    Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. NEJM. 2015;372:825–834.CrossRefPubMedGoogle Scholar
  2. 2.
    Beran V, Chmelar D, Vobejdova J, et al. Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains. Folia Microbiol. 2014;59:209–215.CrossRefGoogle Scholar
  3. 3.
    Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423–427.CrossRefPubMedGoogle Scholar
  4. 4.
    Zainah H, Hassan M, Sheikh-Sroujieh L, et al. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci. 2015;60:181–185.CrossRefPubMedGoogle Scholar
  5. 5.
    van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEJM. 2013;368:407–415.CrossRefPubMedGoogle Scholar
  6. 6.
    Quera R, Espinoza R, Estay C, et al. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection. J Crohn’s Colitis. 2014;8:252–253.CrossRefGoogle Scholar
  7. 7.
    Kelly CR, Ihunnah C, Monika Fischer, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065–1071.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA
  2. 2.Walnut CreekUSA
  3. 3.Division of GastroenterologyUniversity of California-San FranciscoSan FranciscoUSA

Personalised recommendations